BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

750 related articles for article (PubMed ID: 31520437)

  • 1. Left atrial appendage closure: A therapy uniquely suited for specific populations of patients with atrial fibrillation.
    Black-Maier E; Piccini JP; Granger CB
    J Cardiovasc Electrophysiol; 2019 Dec; 30(12):2968-2976. PubMed ID: 31520437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Propensity-Matched Comparison of Oral Anticoagulation Versus Antiplatelet Therapy After Left Atrial Appendage Closure With WATCHMAN.
    Søndergaard L; Wong YH; Reddy VY; Boersma LVA; Bergmann MW; Doshi S; Kar S; Sievert H; Wehrenberg S; Stein K; Holmes DR
    JACC Cardiovasc Interv; 2019 Jun; 12(11):1055-1063. PubMed ID: 31171282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bleeding Outcomes After Left Atrial Appendage Closure Compared With Long-Term Warfarin: A Pooled, Patient-Level Analysis of the WATCHMAN Randomized Trial Experience.
    Price MJ; Reddy VY; Valderrábano M; Halperin JL; Gibson DN; Gordon N; Huber KC; Holmes DR
    JACC Cardiovasc Interv; 2015 Dec; 8(15):1925-1932. PubMed ID: 26627989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Left Atrial Appendage Closure Versus Direct Oral Anticoagulants in High-Risk Patients With Atrial Fibrillation.
    Osmancik P; Herman D; Neuzil P; Hala P; Taborsky M; Kala P; Poloczek M; Stasek J; Haman L; Branny M; Chovancik J; Cervinka P; Holy J; Kovarnik T; Zemanek D; Havranek S; Vancura V; Opatrny J; Peichl P; Tousek P; Lekesova V; Jarkovsky J; Novackova M; Benesova K; Widimsky P; Reddy VY;
    J Am Coll Cardiol; 2020 Jun; 75(25):3122-3135. PubMed ID: 32586585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The budget impact of left atrial appendage closure compared with adjusted-dose warfarin and dabigatran etexilate for stroke prevention in atrial fibrillation.
    Amorosi SL; Armstrong S; Da Deppo L; Garfield S; Stein K
    Europace; 2014 Aug; 16(8):1131-6. PubMed ID: 24687964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials.
    Reddy VY; Doshi SK; Kar S; Gibson DN; Price MJ; Huber K; Horton RP; Buchbinder M; Neuzil P; Gordon NT; Holmes DR;
    J Am Coll Cardiol; 2017 Dec; 70(24):2964-2975. PubMed ID: 29103847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness of Left Atrial Appendage Closure for Stroke Reduction in Atrial Fibrillation: Analysis of Pooled, 5-Year, Long-Term Data.
    Reddy VY; Akehurst RL; Gavaghan MB; Amorosi SL; Holmes DR
    J Am Heart Assoc; 2019 Jul; 8(13):e011577. PubMed ID: 31230500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical impact of incomplete left atrial appendage closure with the Watchman Device in patients with atrial fibrillation: a PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation) substudy.
    Viles-Gonzalez JF; Kar S; Douglas P; Dukkipati S; Feldman T; Horton R; Holmes D; Reddy VY
    J Am Coll Cardiol; 2012 Mar; 59(10):923-9. PubMed ID: 22381428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Device-Related Thrombus After Left Atrial Appendage Closure: Incidence, Predictors, and Outcomes.
    Dukkipati SR; Kar S; Holmes DR; Doshi SK; Swarup V; Gibson DN; Maini B; Gordon NT; Main ML; Reddy VY
    Circulation; 2018 Aug; 138(9):874-885. PubMed ID: 29752398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Left Atrial Appendage: Target for Stroke Reduction in Atrial Fibrillation.
    Ramlawi B; Abu Saleh WK; Edgerton J
    Methodist Debakey Cardiovasc J; 2015; 11(2):100-3. PubMed ID: 26306127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Left Atrial Appendage Closure as an Alternative to Warfarin for Stroke Prevention in Atrial Fibrillation: A Patient-Level Meta-Analysis.
    Holmes DR; Doshi SK; Kar S; Price MJ; Sanchez JM; Sievert H; Valderrabano M; Reddy VY
    J Am Coll Cardiol; 2015 Jun; 65(24):2614-2623. PubMed ID: 26088300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of percutaneous left atrial appendage closure with the Amplatzer cardiac plug in patients with atrial fibrillation and contraindications to anticoagulation.
    Wiebe J; Bertog S; Franke J; Wettstein O; Lehn K; Hofmann I; Vaskelyte L; Sievert H
    Catheter Cardiovasc Interv; 2014 Apr; 83(5):796-802. PubMed ID: 24327462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial.
    Holmes DR; Kar S; Price MJ; Whisenant B; Sievert H; Doshi SK; Huber K; Reddy VY
    J Am Coll Cardiol; 2014 Jul; 64(1):1-12. PubMed ID: 24998121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-Term Oral Anticoagulation Versus Antiplatelet Therapy Following Transcatheter Left Atrial Appendage Closure.
    Asmarats L; O'Hara G; Champagne J; Paradis JM; Bernier M; O'Connor K; Beaudoin J; Junquera L; Del Val D; Muntané-Carol G; Côté M; Rodés-Cabau J
    Circ Cardiovasc Interv; 2020 Aug; 13(8):e009039. PubMed ID: 32772571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Left atrial appendage closure.
    Lin AC; Knight BP
    Prog Cardiovasc Dis; 2015; 58(2):195-201. PubMed ID: 26241302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An under-recognized high-risk atrial fibrillation population: Analyzing transcatheter mitral valve repair patients for left atrial appendage closure device application.
    Lane CE; Eleid MF; Holmes DR
    Catheter Cardiovasc Interv; 2019 Aug; 94(2):274-279. PubMed ID: 30953408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of percutaneous left atrial appendage closure to prevent thromboembolic events in atrial fibrillation patients with high stroke and bleeding risk.
    Seeger J; Bothner C; Dahme T; Gonska B; Scharnbeck D; Markovic S; Rottbauer W; Wöhrle J
    Clin Res Cardiol; 2016 Mar; 105(3):225-9. PubMed ID: 26318322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic review on left atrial appendage closure with the LAmbre device in patients with non-valvular atrial fibrillation.
    Ali M; Rigopoulos AG; Mammadov M; Torky A; Auer A; Matiakis M; Abate E; Bakogiannis C; Tzikas S; Bigalke B; Sedding D; Noutsias M
    BMC Cardiovasc Disord; 2020 Feb; 20(1):78. PubMed ID: 32050904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thromboembolic events and need for anticoagulation therapy following left atrial appendage occlusion in patients with electrical isolation of the appendage.
    Gadiyaram VK; Mohanty S; Gianni C; Trivedi C; Al-Ahmad A; Burkhardt DJ; Gallinghouse JG; Hranitzky PM; Horton RP; Sanchez JE; Della Rocca DG; Di Biase L; Price MJ; Couts L; Gibson D; Natale A
    J Cardiovasc Electrophysiol; 2019 Apr; 30(4):511-516. PubMed ID: 30623500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Net Clinical Benefit of Left Atrial Appendage Closure Versus Warfarin in Patients With Atrial Fibrillation: A Pooled Analysis of the Randomized PROTECT-AF and PREVAIL Studies.
    Brouwer TF; Whang W; Kuroki K; Halperin JL; Reddy VY
    J Am Heart Assoc; 2019 Dec; 8(23):e013525. PubMed ID: 31752643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.